Lupin is currently trading at RS 2134.10, up by 45.25 points or 2.17% from its previous close of RS 2088.85 on the BSE.

The stock opened at RS 2087.90 and has touched an intraday high of RS 2135.70 and a low of RS 2085.00. A total of 9279 shares have been traded on the counter so far.

Belonging to the BSE group 'A', the stock with a face value of RS 2 has seen a 52-week high of RS 2403.45 (as on January 2, 2025) and a 52-week low of RS 1493.75 (as on June 4, 2024). Over the past week, the stock has fluctuated between RS 2139.00 and RS 1929.00. The company’s current market capitalization stands at RS 97047.47 crore.

Promoter holding in the company is at 46.92%, while institutions and non-institutions hold 46.88% and 6.20% respectively.

In a significant development, Lupin’s wholly owned subsidiary, Lupin Diagnostics (LDL), has secured 100% NABL (National Accreditation Board for Testing and Calibration Laboratories) accreditation across all its greenfield labs. This milestone underlines LDL’s stringent quality standards and its commitment to delivering reliable, high-quality diagnostic services. The accreditation reinforces the company's promise of accuracy and timeliness in patient diagnostics.

Lupin is a globally recognized, innovation-driven pharmaceutical company engaged in the production, development, and marketing of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs).